Clinicial response to IL15 and mogamuliziumab. Duration of response (A), best response (B), circulating NK cells (C), and circulating tumor cells (D) after treatment with rhIL-15 and mogamulizumab. Each patient is represented by a consistent color in panels A-D; gray color in panel A indicates patients who were not evaluable in other panels. NE, not evaluable; PR, partial response; PD, progressive disease.